世界のポリオワクチン市場-2025-2033年

世界のポリオワクチン市場は、2024年に8億477万米ドルに達し、2033年には12億4,917万米ドルに達すると予測され、予測期間2025-2033年のCAGRは5.6%で成長すると予測されます。

世界のポリオワクチン市場には、ポリオウイルスによるウイルス性疾患であるポリオ性脊髄炎の予防を目的としたワクチンの製造、流通、投与が含まれます。この市場には、主に経口ワクチン（OPV）と不活化ワクチン（IPV）の2種類があります。それぞれのワクチンには異なる特徴、投与方法、公衆衛生への影響があります。

OPVは点滴の形で経口投与されるため、配布が容易で集団予防接種キャンペーンに適しています。OPVには弱毒化ポリオウイルス株が含まれています。つまり、健康な人では発病しない程度に弱毒化されていますが、腸内ではまだウイルスが増殖する可能性があります。

IPVは注射（筋肉内または皮下）で投与されるため、投与には訓練を受けたヘルスケア専門家が必要です。IPVには死滅（不活化）ポリオウイルスが含まれているため、病気を引き起こしたり、体内で複製したりすることはありません。IPVは、体液性免疫（血流中の抗体）を誘導することで個人をポリオから保護しますが、接種を受けた人がウイルスを排出することはないため、地域レベルの免疫は得られません。

OPVとIPVはいずれも、世界のポリオ予防接種戦略において重要な役割を果たしています。OPVとIPVのどちらを使用するかは、地域の疫学、予防接種方針、費用、ポリオ撲滅に関する公衆衛生の目標などの要因によって決まることが多いです。ポリオ撲滅に向けた世界の取り組みが続く中、効果的な予防接種戦略のためには、これらのワクチンの違いや用途を理解することが不可欠です。こうした要因が、世界のポリオワクチン市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

政府の取り組み

政府の取り組みは、世界のポリオワクチン市場における重要な促進要因であり、予防接種戦略を大きく形成し、公衆衛生の結果に影響を与えています。これらのイニシアチブは、予防接種率を向上させ、ワクチンへのアクセスを確保し、ポリオ撲滅に向けた取り組みを進める上で極めて重要です。各国政府は、定期的な予防接種スケジュールにポリオワクチンを組み込んだ包括的な予防接種プログラムを策定しています。例えば、インドの普遍的予防接種プログラム（UIP）は、高い接種率を達成し、ポリオ撲滅の成功に貢献しました。

ワクチンの調達、配布、投与には政府資金が不可欠です。多くの国では、ポリオ予防接種キャンペーンを支援するために多額の予算が割り当てられており、特に十分なサービスが行き届いていない地域のすべての子どもたちにワクチンが行き渡るようにしています。世界ポリオ撲滅推進計画（GPEI）は、各国政府から大きなコミットメントを得ています。

例えば、2023年12月、新規経口ポリオワクチン2型（nOPV2）は、世界保健機関（WHO）の緊急使用リスト（EUL）の下での使用から、完全な認可とWHOの事前資格認定に移行した最初のワクチンとなり、歴史的なマイルストーンを達成しました。この重要な進歩は、ポリオウイルスに関連する公衆衛生の課題に対するnOPV2の有効性を強調するものであり、ポリオ撲滅に向けた世界の取り組みにおいて極めて重要な一歩を踏み出したことを意味します。

また、2024年1月、世界保健機関（WHO）は、新規経口ポリオワクチン2型（nOPV2）の予備承認を与え、ポリオと闘う世界の取り組みにおいて重要な成果を示しました。このプレクオリフィケーションは、WHOの緊急使用リスト（EUL）の下で使用されているワクチンがこのステータスを得た初めての例であり、特に注目に値します。さらに、撲滅活動に対する需要の高まりも、世界のポリオワクチン市場の拡大に寄与しています。

サプライチェーンの混乱

ポリオワクチンのサプライチェーンは、主に経口ポリオワクチンに使用されるセービン株などの必須成分を限られたメーカーに依存しているため、途絶の影響を受けやすいです。このような依存関係は、ポリオ撲滅を目指す継続的な予防接種活動にとって不可欠なワクチンの安定供給を維持する上で、大きな課題となっています。

経口ポリオワクチン（OPV）の製造は、少数の製造業者に集中しています。バイオ・ファルマ社（インドネシア）、グラクソ・スミスクライン社（GSK）（英国）、サノフィ・パスツール社（フランス）などが、OPVの主要な大量生産企業です。このように供給者の数が少ないため、技術的な問題、規制上の障害、自然災害などによる生産能力の中断は、ワクチンの供給不足につながる可能性があります。したがって、上記の要因が世界のポリオワクチン市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 政府の取り組み
  • 抑制要因
    • サプライチェーンの混乱
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 製品タイプ別

• Inactivated Polio Vaccine (IPV)
• Oral Polio Vaccine (OPV)

第7章 カテゴリ別

• 二価
• 三価
• その他

第8章 投与経路別

• オーラル
• 筋肉内
• 皮下注射

第9章 年齢層別

• 小児
• 成人

第10章 最終用途別

• 病院
• 専門クリニック
• 公共サービス
• その他

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第13章 企業プロファイル

• Sanofi
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 過去および予測の製品販売
    • 製品販売量
  • 財務概要
    • 会社の収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Serum Institute of India Pvt. Ltd.
• Bharat Biotech.
• GSK plc
• Merck & Co., Inc.
• PT Bio Farma（Persero）
• Panacea Biotec
• HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD.
• SINOVAC
• Bavarian Nordic

第14章 付録

The global polio vaccine market reached US$ 804.77 million in 2024 and is expected to reach US$ 1,249.17 million by 2033, growing at a CAGR of 5.6 % during the forecast period 2025-2033.

The global polio vaccines market encompasses the production, distribution, and administration of vaccines aimed at preventing poliomyelitis, a viral disease caused by the poliovirus. This market includes two main types of vaccines the oral polio vaccine (OPV) and the inactivated polio vaccine (IPV). Each vaccine has distinct characteristics, administration methods, and implications for public health.

OPV is administered orally in the form of liquid drops, making it easy to distribute and suitable for mass immunization campaigns. It contains live attenuated strains of the poliovirus. This means that while the virus is weakened enough not to cause disease in healthy individuals, it can still replicate in the intestines.

IPV is administered via injection (intramuscular or subcutaneous), requiring trained healthcare professionals for administration. IPV contains killed (inactivated) poliovirus, meaning it cannot cause disease or replicate within the body. While IPV provides individual protection against polio by inducing humoral immunity (antibodies in the bloodstream), it does not provide community-level immunity since recipients do not shed the virus.

Both OPV and IPV play critical roles in polio vaccination strategies worldwide. The choice between using OPV or IPV often depends on factors such as local epidemiology, vaccination policies, cost considerations, and public health goals related to polio eradication. As global efforts continue to eliminate polio, understanding these vaccines' differences and applications is essential for effective immunization strategies. These factors have driven the global polio vaccine market expansion.

Market Dynamics: Drivers & Restraints

Government initiatives

Government initiatives are vital drivers in the global polio vaccines market, significantly shaping vaccination strategies and influencing public health outcomes. These initiatives are crucial for improving immunization coverage, ensuring vaccine accessibility, and advancing efforts toward the eradication of polio. Governments establish comprehensive immunization programs that incorporate polio vaccines into routine vaccination schedules. For instance, India's Universal Immunization Program (UIP) has been instrumental in achieving high vaccination coverage rates, contributing to the country's success in eradicating polio.

Government funding is essential for the procurement, distribution, and administration of vaccines. Many countries allocate substantial budgets to support polio vaccination campaigns, ensuring that vaccines reach all children, particularly in underserved areas. The Global Polio Eradication Initiative (GPEI) has received significant commitments from governments, which are critical for sustaining eradication efforts.

For instance, in December 2023, the novel oral polio vaccine type 2 (nOPV2) achieved a historic milestone by becoming the first vaccine to transition from use under the World Health Organization (WHO) Emergency Use Listing (EUL) to full licensure and WHO prequalification. This significant advancement underscores the effectiveness of nOPV2 in addressing public health challenges associated with poliovirus and marks a crucial step in the global effort to combat polio.

Also, in January 2024, the World Health Organization (WHO) granted prequalification to the novel oral polio vaccine type 2 (nOPV2), marking a significant achievement in the global effort to combat polio. This prequalification is particularly notable as it represents the first instance of a vaccine receiving this status while being utilized under the WHO's Emergency Use Listing (EUL). Moreover, the rising demand for focus on eradication initiatives contributes to the global polio vaccine market expansion.

Supply Chain Disruptions

The polio vaccine supply chain is vulnerable to disruptions primarily due to the reliance on a limited number of manufacturers for essential components, such as the Sabin strains used in oral polio vaccines. This dependence poses significant challenges in maintaining a consistent supply of vaccines, which is critical for ongoing immunization efforts aimed at eradicating polio.

The production of oral polio vaccines (OPV) is concentrated among a few manufacturers. Companies like Bio Farma (Indonesia), GlaxoSmithKline (GSK) (UK), and Sanofi Pasteur (France) are among the primary bulk producers of OPV. With such a small pool of suppliers, any disruptions in their production capabilities whether due to technical issues, regulatory hurdles, or natural disasters can lead to significant shortages in vaccine availability. Thus, the above factors could be limiting the global polio vaccine market's potential growth.

Segment Analysis

The global polio vaccine market is segmented based on product type, category, route of administration, age group, end-user, and region.

Product Type:

The inactivated polio vaccine (IPV) segment is expected to dominate the global polio vaccine market share

The inactivated polio vaccine (IPV) segment holds a major portion of the global polio vaccine market share and is expected to continue to hold a significant portion of the global polio vaccine market share during the forecast period. The inactivated polio vaccine (IPV) segment is a critical component of the global polio vaccines market, recognized for its safety and effectiveness in preventing poliomyelitis. IPV is an injectable vaccine that contains killed poliovirus, which eliminates the risk of vaccine-derived poliovirus associated with oral polio vaccines (OPV).

IPV consists of inactivated strains of the poliovirus and is administered via injection. This method stimulates an immune response by encouraging the production of antibodies without causing disease, making it a safe option, particularly in populations where polio remains a threat. Furthermore, key players' strategies such as partnerships & collaborations would drive this segment's growth in the global polio vaccine market.

For instance, in June 2024, Sanofi and Biovac announced an innovative partnership aimed at enhancing polio vaccine manufacturing capabilities in Africa. This collaboration is particularly significant as it marks the establishment of the first local production of inactivated polio vaccines (IPV) on the continent, which is expected to meet the needs of over 40 African countries. These factors have solidified the segment's position in the global polio vaccine market.

Geographical Analysis

North America is expected to hold a significant position in the global polio vaccine market share

North America holds a substantial position in the global polio vaccine market and is expected to hold most of the market share. The resurgence of infectious diseases in various regions has increased awareness of the need for vaccinations, including polio vaccines. Public health responses to outbreaks can lead to additional funding and resources allocated toward immunization campaigns.

Ongoing advancements in vaccine technology enhance the safety and efficacy of polio vaccines. Innovations such as the development of the novel oral polio vaccine type 2 (nOPV2) and improvements in production methods contribute to more effective immunization strategies, boosting confidence among healthcare providers and the public. Growing awareness about the importance of vaccination among the public is driving demand for polio vaccines. Educational campaigns aimed at informing communities about the risks associated with polio and the benefits of vaccination have led to increased participation in immunization programs.

Government initiatives play a vital role in promoting polio vaccination. In North America, comprehensive immunization programs are established, supported by public health policies that require vaccinations for school entry and other public health mandates. These programs ensure broad access to polio vaccines, resulting in high vaccination coverage rates.

For instance, in January 2024, the Global Polio Eradication Initiative (GPEI) launched the Make Polio History campaign to garner support for global polio eradication efforts. This initiative is particularly noteworthy as it features the novel oral polio vaccine type 2 (nOPV2), developed specifically in response to outbreaks of poliovirus type 2 in the U.S. Thus, the above factors are consolidating the region's position as a dominant force in the global polio vaccine market.

Asia Pacific is growing at the fastest pace in the global polio vaccine market share

Asia Pacific holds the fastest pace in the global polio vaccine market and is expected to hold most of the market share. The growing population in Asia-Pacific countries leads to an increased number of births, which directly correlates with a higher demand for polio vaccinations. As more children are born, there is an urgent need to ensure they receive timely vaccinations against polio.

Governments across the Asia-Pacific region have established comprehensive immunization programs aimed at eradicating polio. Initiatives such as the Polio Eradication Strategy 2022-2026 by the Global Polio Eradication Initiative (GPEI) reflect a strong commitment to public health. These programs facilitate widespread access to vaccines and integrate polio vaccination into routine immunization schedules.

There is an increasing awareness of the importance of vaccination among the public, which is driving demand for polio vaccines. Educational campaigns conducted by governments and non-governmental organizations inform communities about the risks associated with polio and the benefits of vaccination, resulting in higher participation rates in immunization programs. Continuous improvements in vaccine technology enhance the safety and efficacy of polio vaccines. Innovations such as the development of the novel oral polio vaccine type 2 (nOPV2) contribute to more effective immunization strategies, increasing confidence among healthcare providers and the public.

Furthermore, key players' strategies such as partnerships & collaborations, and innovative launches would drive this global polio vaccine market growth. For instance, in April 2024, Bharat Biotech announced a collaboration with Bilthoven Biologicals B.V. (BBio), a wholly-owned subsidiary of Serum Institute of India Private Limited based in the Netherlands. This partnership aims to enhance the production and supply security of Oral Polio Vaccines (OPV).

Also, in April 2024, Sanofi obtained approval for its new inactivated polio vaccine, IMOVAX-Polio, which is set to replace its previous product, ShanIPV, in India. This decision comes in response to concerns about a potential shortage of polio vaccines following Sanofi's announcement to discontinue ShanIPV due to operational challenges at its manufacturing facilities. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global polio vaccine market.

Competitive Landscape

The major global players in the polio vaccine market include Sanofi, Serum Institute of India Pvt. Ltd., Bharat Biotech., GSK plc, Merck & Co., Inc., PT Bio Farma (Persero), Panacea Biotec, HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD., SINOVAC, and Bavarian Nordic.

Key Developments

• In January 2025, Union Health Secretary Apurva Chandra visited Bilthoven Biologicals, a leading pharmaceutical company in the Netherlands. During this visit, he engaged in a productive meeting with CEO Juergen Kwik. The primary focus of their discussions was to explore potential partnerships and collaborations aimed at enhancing the production of vaccines, particularly the Oral Polio Vaccine (OPV).
• In November 2024, Sudan launched a new polio vaccination campaign aimed at safeguarding children under the age of five from poliovirus. This initiative is a direct response to the ongoing challenges posed by recent outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2) detected in the country. All these factors demand the global polio vaccine market.
• In April 2024, Sinovac Biotech Ltd. announced that its Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains (Five-Dose), known as msIPV, received authorization for market use from the China National Medical Products Administration (NMPA). This approval represents a significant advancement in the fight against polio, particularly in enhancing vaccination efforts within China and potentially extending its impact to other regions.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global polio vaccine market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Category
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Age Group
• 3.5. Snippet by End-User
• 3.6. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Government initiatives
  • 4.1.2. Restraints
    • 4.1.2.1. Supply Chain Disruptions
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Inactivated Polio Vaccine (IPV)*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Oral Polio Vaccine (OPV)

7. By Category

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  • 7.1.2. Market Attractiveness Index, By Category
• 7.2. Bivalent*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Trivalent
• 7.4. Others

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Oral*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Intramuscular
• 8.4. Subcutaneous Injection

9. By Age Group

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 9.1.2. Market Attractiveness Index, By Age Group
• 9.2. Pediatric*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Adults

10. By End-User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.1.2. Market Attractiveness Index, By End-User
• 10.2. Hospitals *
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Specialty Clinics
• 10.4. Public Services
• 10.5. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.8.1. U.S.
    • 11.2.8.2. Canada
    • 11.2.8.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.8.1. Germany
    • 11.3.8.2. U.K.
    • 11.3.8.3. France
    • 11.3.8.4. Spain
    • 11.3.8.5. Italy
    • 11.3.8.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.8.1. Brazil
    • 11.4.8.2. Argentina
    • 11.4.8.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.8.1. China
    • 11.5.8.2. India
    • 11.5.8.3. Japan
    • 11.5.8.4. South Korea
    • 11.5.8.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Sanofi *
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio
    • 13.1.2.1. Product Description
    • 13.1.2.2. Product Key Performance Indicators (KPIs)
    • 13.1.2.3. Historic and Forecasted Product Sales
    • 13.1.2.4. Product Sales Volume
  • 13.1.3. Financial Overview
    • 13.1.3.1. Company Revenue's
    • 13.1.3.2. Geographical Revenue Shares
    • 13.1.3.3. Revenue Forecasts
  • 13.1.4. Key Developments
    • 13.1.4.1. Mergers & Acquisitions
    • 13.1.4.2. Key Product Development Activities
    • 13.1.4.3. Regulatory Approvals etc.
  • 13.1.5. SWOT Analysis
• 13.2. Serum Institute of India Pvt. Ltd.
• 13.3. Bharat Biotech.
• 13.4. GSK plc
• 13.5. Merck & Co., Inc.
• 13.6. PT Bio Farma (Persero)
• 13.7. Panacea Biotec
• 13.8. HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD.
• 13.9. SINOVAC
• 13.10. Bavarian Nordic

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us